Riassunto
Nell’era dell’imaging molecolare ciò che si chiede alla diagnostica per immagini è avere buona accuratezza nella diagnosi precoce di un’alterazione patologica, sia benigna sia, soprattutto, maligna. La criticità di questo aspetto risulta indiscutibile dal punto di vista oncologico e terapeutico, in cui è di primaria importanza superare i limiti dell’evidenza morfologica; in altre parole, la possibilità di identificare un focus patologico prima ancora che sia morfologicamente apprezzabile cambia necessariamente l’outcome del trattamento [1]. È chiaro che i requisiti richiesti esaltano l’aspetto funzionale delle tecniche utilizzate, come per la diffusione, di cui si è trattato nel capitolo 13. Le altre tecniche che sicuramente esaltano l’aspetto funzionale dell’esame di RM sono la spettroscopia a immagini (1H-MRSI) e lo studio dinamico-perfusionale (DCE-MR). Entrambe offrono la visione di due aspetti fondamentali, riguardanti rispettivamente il metabolismo e la vascolarizzazione, che indirizzano indubbiamente verso una più corretta interpretazione diagnostica, quando ancora la lesione si trova in uno stato di pre-evidenza clinico-morfologica. In tale contesto la RM assume significato di completezza e, secondo l’acquisizione anglosassone, diventa un one-stop-shop examination.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Bibliografia
Jadvar H (2009) Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging 8(2):56–64
Arora R, Koch MO, Eble JN et al (2004) Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100:2362–2366
Giannoni E, Fiaschi T, Ramponi G, Chiarugi P (2009) Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 28(20):2074–2086
Weidner N (1995) Intratumoral microvascular density as a prognostic factor in cancer. Am J Pathol 147:9–19
Folkman J (1989) What is evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 82:4–6
Foster D, Xu L (2003) Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1(11):789–800
Kim HJ, Lee YH, Kim CK (2007) Biomarkers of muscle and cartilage damage and inflammation during a 200 km run. Eur J Appl Physiol 99(4):443–447
Costello LC, Franklin RB (2002) Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm Metab Res 34(8):417–424
Zakian KL, Shukla-Dave A, Ackerstaff E et al (2008) 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark 4(4–5): 263–276
Kurhanewicz J, Vigneron DB, Nelson SJ (2000) Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2:166–189
Sciarra A, Salciccia S, Panebianco V (2008) Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. Eur Urol 54(3):485–488
Claus FG, Hricak H, Hattery RR (2004) Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 24 Suppl 1:S167–180
Zakian KL, Sircar K, Hricak H et al (2005) Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234(3):804–814
Prostate cancer detection: magnetic resonance (MR) spectroscopy imaging. Joan C. Villanova, J. Barcelòm Abdominal Imaging (2007) 32:253–261
Fütterer JJ, Heijmink SW, Scheenen TW et al (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241(2):449–458
Hricak H, Choyke PL, Eberhardt SC et al (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28–53
Nakashima J, Tanimoto A, Imai Y et al (2004) Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 64(1):101–105
Scheenen TW, Heijmink SW, Roell SA et al (2007) Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 245: 507–516
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867.
Dvorak HF, Nagy JA, Feng D et al (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97–132
Somford DM, Fütterer JJ, Hambrock T, Barentsz JO (2008) Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 16(4):685–695
Valerio MC, Panebianco V, Sciarra A et al (2009) Classification of prostatic disease by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data. NMR Biomed [Jul 3 Epub ahead of print]
Sandblom G, Ladjevardi S, Garmo H, Varenhorst E (2008) The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate. Cancer 112(4):813–819
Stefanou D, Batistatou A, Kamina S et al (2004) Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18(2):155–160
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Panebianco, V., Lisi, D., Bernardo, S. (2010). Carcinoma della prostata: pattern RM metabolici e di vascolarizzazione. In: Passariello, R., Panebianco, V., Di Silverio, F., Sciarra, A. (eds) Imaging RM della prostata. Springer, Milano. https://doi.org/10.1007/978-88-470-1516-6_14
Download citation
DOI: https://doi.org/10.1007/978-88-470-1516-6_14
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1515-9
Online ISBN: 978-88-470-1516-6
eBook Packages: MedicineMedicine (R0)